Skip to main content

Dr Athina Giannoudis
BSc, MSc, PhD

Lecturer
School of Dentistry
Part of
Institute of Life Course & Medical Sciences
Faculty of Health and Life Sciences

Contact

A.Giannoudis@liverpool.ac.uk

Publications

Selected publications

  1. The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article - 2013)
  2. Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors (Journal article - 2011)
  3. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia (Journal article - 2008)
  4. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression (Journal article - 2022)
  5. The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach (Journal article - 2022)
  6. Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival (Journal article - 2021)
  7. A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival (Journal article - 2019)
  8. Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process (Journal article - 2018)
  9. Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases (Conference Paper - 2017)
  10. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article - 2014)
What type of publication do you want to show?

2024

Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2-Positive Disease.

Bhogal, T., Giannoudis, A., Sokol, E., Ali, S., & Palmieri, C. (2024). Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2-Positive Disease.. JCO precision oncology, 8, e2300639. doi:10.1200/po.23.00639

DOI
10.1200/po.23.00639
Journal article

Targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors

DOI
10.21203/rs.3.rs-4206376/v1
Preprint

A Bioinformatic Characterisation of the Glyolytic Enzyme ENO1 as a Biomarker of Breast Cancer Progression

DOI
10.21203/rs.3.rs-3853453/v1
Preprint

2023

ENO1 as a biomarker of breast cancer progression and metastasis – a bioinformatic approach

DOI
10.1101/2023.11.01.23297919
Preprint

Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases

Giannoudis, A., Sokol, E., Ramkissoon, S., Bhogal, T., Ross, J., McGregor, K., . . . Palmieri, C. (2023). Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. In CANCER RESEARCH Vol. 83. doi:10.1158/1538-7445.SABCS22-P5-14-10

DOI
10.1158/1538-7445.SABCS22-P5-14-10
Conference Paper

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors

DOI
10.21203/rs.3.rs-2484456/v1
Preprint

2022

Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression

Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P. S., . . . Palmieri, C. (2022). Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO OPEN, 7(6). doi:10.1016/j.esmoop.2022.100636

DOI
10.1016/j.esmoop.2022.100636
Journal article

The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis

Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P., . . . Palmieri, C. (2022). The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis. In ANNALS OF ONCOLOGY Vol. 33 (pp. S132). doi:10.1016/j.annonc.2022.03.035

DOI
10.1016/j.annonc.2022.03.035
Conference Paper

Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases

Bhogal, T., Sokol, E., Ramkissoon, S., Giannoudis, A., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-P5-07-04

DOI
10.1158/1538-7445.SABCS21-P5-07-04
Conference Paper

Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors

Giannoudis, A., Sokol, E., Ramkissoon, S. H., Bhogal, T., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-PD4-09

DOI
10.1158/1538-7445.SABCS21-PD4-09
Conference Paper

2021

Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival

Giannoudis, A., Sartori, A., Eastoe, L., Zakaria, R., Charlton, C., Hickson, N., . . . Palmieri, C. (2021). Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. BREAST CANCER RESEARCH AND TREATMENT, 190(2), 241-253. doi:10.1007/s10549-021-06364-8

DOI
10.1007/s10549-021-06364-8
Journal article

Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival

DOI
10.21203/rs.3.rs-377753/v1
Preprint

1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.

Pradubyat, N., Giannoudis, A., Elmetwali, T., Mahalapbutr, P., Palmieri, C., Mitrpant, C., & Ketchart, W. (2021). 1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.. Planta Medica. doi:10.1055/a-1307-3997

DOI
10.1055/a-1307-3997
Journal article

2020

A systematic review of the receptor status and genomic landscape of breast cancer brain metastases

Morgan, A. J., Giannoudis, A., & Palmieri, C. (2020). A systematic review of the receptor status and genomic landscape of breast cancer brain metastases. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-05-22

DOI
10.1158/1538-7445.SABCS19-P4-05-22
Conference Paper

The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer

Giannoudis, A., Malki, M. I., Mohammed, H., Rudraraju, B., Menon, S., Ali, S., . . . Palmieri, C. (2020). The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P6-04-18

DOI
10.1158/1538-7445.SABCS19-P6-04-18
Conference Paper

UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis

Giannoudis, A., Eastoe, L., Charlton, C., Hickson, N., Zakaria, R., Platt-Higgins, A., . . . Palmieri, C. (2020). UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-09-07

DOI
10.1158/1538-7445.SABCS19-P4-09-07
Conference Paper

2019

Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer

Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-05-02

DOI
10.1158/1538-7445.SABCS18-P6-05-02
Conference Paper

2018

2017

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases

Giannoudis, A., Zakaria, R., Platt-Higgins, A., Syed, K. A. R., Ashton, K., Dawson, T., . . . Palmieri, C. (2017). Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.SABCS16-P2-03-04

DOI
10.1158/1538-7445.SABCS16-P2-03-04
Conference Paper

2016

A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer

Palmieri, C., Rudraraju, B., Giannoudis, A., Moore, D., Shaw, J., Chan, S., . . . Abdel-Fatah, T. M. A. (2016). A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-08-17

DOI
10.1158/1538-7445.SABCS15-P5-08-17
Conference Paper

2015

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

Redaelli, S., Perini, P., Ceccon, M., Piazza, R., Rigolio, R., Mauri, M., . . . Gambacorti-Passerini, C. (2015). In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. JOURNAL OF HEMATOLOGY & ONCOLOGY, 8. doi:10.1186/s13045-015-0179-4

DOI
10.1186/s13045-015-0179-4
Journal article

C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691

DOI
10.3324/haematol.2014.115691
Journal article

2014

Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176

DOI
10.1038/clpt.2014.176
Journal article

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972

DOI
10.3324/haematol.2013.101972
Journal article

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

Rudraraju, B., Droog, M., Abdel-Fatah, T. M. A., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 147(2), 295-309. doi:10.1007/s10549-014-3098-0

DOI
10.1007/s10549-014-3098-0
Journal article

Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.

Journal article

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

Rudraraju, B., Droog, M., Abdel-Fatah, T. M., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 147(2), 295-309.

Journal article

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38

DOI
10.1038/leu.2014.38
Journal article

2013

Transport of gabapentin by LAT1 (SLC7A5)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Raedisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). BIOCHEMICAL PHARMACOLOGY, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI
10.1016/j.bcp.2013.03.022
Journal article

Transport of gabapentin by LAT1 (SLC7A5)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Rädisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI
10.1016/j.bcp.2013.03.022
Journal article

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035

DOI
10.1182/blood-2012-01-405035
Journal article

10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML)

Lucas, C., Harrisl, R., Giannoudis, A., & Clark, R. (2013). 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML). In HAEMATOLOGICA Vol. 98 (pp. 55). Retrieved from https://www.webofscience.com/

Conference Paper

10058-f4 a small molecule c-myc inhibitor decreases CIP2A and reduces BCR-ABL-1 tyrosine kinase activity in chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., & Clark, R. E. (2013). 10058-f4 a small molecule c-myc inhibitor decreases CIP2A and reduces BCR-ABL-1 tyrosine kinase activity in chronic myeloid leukaemia. Haematologica, 98, S1.

Journal article

TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS

Giannoudis, A., Davies, A., Harris, R., Lucas, C., Pirmohamed, M., & Clark, R. (2013). TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 400). Retrieved from https://www.webofscience.com/

Conference Paper

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.

Journal article

The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations

Francis, S., Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2013). The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations. BRITISH JOURNAL OF HAEMATOLOGY, 161, 58-59. Retrieved from https://www.webofscience.com/

Journal article

Transcript levels and copy number variation of the ABCC3 efflux transporter can predict clinical outcome in imatinib-treated chronic myeloid leukaemia patients

Giannoudis, A., Davies, A., Harris, R. J., Lucas, C. M., Pirmohamed, M., & Clark, R. E. (2013). Transcript levels and copy number variation of the ABCC3 efflux transporter can predict clinical outcome in imatinib-treated chronic myeloid leukaemia patients. Haematologica, 98, S1.

Journal article

of gabapentin by LAT1 (SLC7A5)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Radisch, S., . . . Pirmohamed, M. (2013). of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol, 85, 1672-1683.

Journal article

2012

Lamotrigine is a substrate for OCT1 in brain endothelial cells

Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032

DOI
10.1016/j.bcp.2011.12.032
Journal article

DUAL GSTT1 AND GSTM1 GENE DELETIONS INCREASE THE RISK OF IMATINIB FAILURE IN CHRONIC MYELOID LEUKAEMIA (CML)

Davies, A., Giannoudis, A., Wang, L. H., Austin, G., Holyoake, T., Mueller, M., . . . Clark, R. (2012). DUAL GSTT1 AND GSTM1 GENE DELETIONS INCREASE THE RISK OF IMATINIB FAILURE IN CHRONIC MYELOID LEUKAEMIA (CML). In HAEMATOLOGICA Vol. 97 (pp. 207). Retrieved from https://www.webofscience.com/

Conference Paper

Dual GSTT1 and GSTM1 gene deletions increase the risk of imatinib failure in chronic myeloid leukaemia

Davies, A., Giannoudis, A., Wang, L., Austin, G., Holyoake, T., Mueller, M., . . . Clark, R. E. (2012). Dual GSTT1 and GSTM1 gene deletions increase the risk of imatinib failure in chronic myeloid leukaemia. Haematologica, 97, S1.

Journal article

IMATINIB, BUT NOT NILOTINIB, IS ACTIVELY TRANSPORTED BY SLCO1A2 IN CHRONIC MYELOID LEUKAEMIA CELLS

Francis, S., Giannoudis, A., Davies, A., Austin, G., Konig, J., Pirmohammed, M., & Clark, R. (2012). IMATINIB, BUT NOT NILOTINIB, IS ACTIVELY TRANSPORTED BY SLCO1A2 IN CHRONIC MYELOID LEUKAEMIA CELLS. In HAEMATOLOGICA Vol. 97 (pp. 211). Retrieved from https://www.webofscience.com/

Conference Paper

Imatinib, but not nilotinib, is actively transported by SLCO1A2 in chronic myeloid leukaemia cells

Francis, S., Giannoudis, A., Davies, A., Austin, G., König, J., Pirmohamed, M., & Clark, R. E. (2012). Imatinib, but not nilotinib, is actively transported by SLCO1A2 in chronic myeloid leukaemia cells. Haematologica, 97, S1.

Journal article

Lamotrigine is a substrate for OCT1 in brain endothelial cells

Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharm, 83, 805-814.

Journal article

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. EXPERIMENTAL HEMATOLOGY, 40(10), 811-819. doi:10.1016/j.exphem.2012.05.013

DOI
10.1016/j.exphem.2012.05.013
Journal article

Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia. Experimental Hematology, 40, 811-819.

Journal article

2011

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477

DOI
10.1182/blood-2010-08-304477
Journal article

Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors

Muthana, M., Giannoudis, A., Scott, S. D., Fang, H. -Y., Coffelt, S. B., Morrow, F. J., . . . Maitland, N. J. (2011). Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. CANCER RESEARCH, 71(5), 1805-1815. doi:10.1158/0008-5472.CAN-10-2349

DOI
10.1158/0008-5472.CAN-10-2349
Journal article

Correlation of hOCT1 SNPs and clinical outcome in imatinib treated chronic myeloid leukaemia patients; functional significance of M420del and M408V

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Correlation of hOCT1 SNPs and clinical outcome in imatinib treated chronic myeloid leukaemia patients; functional significance of M420del and M408V. In NCRI Cancer Conference (pp. B242). Liverpool: NCRI.

Conference Paper

Correlation of hOCT1 genetic polymorphims with the clinical outcome of chronic myeloid leukaemia patients treated with imatinib

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Correlation of hOCT1 genetic polymorphims with the clinical outcome of chronic myeloid leukaemia patients treated with imatinib. In European School of Haematology CML Annual Meeting (pp. P123). Estoril: ESH.

Conference Paper

Interaction of the common hOCT1 SNPs M420del and M408V is critical in predicting clinical outcome in chronic myeloid leukaemia patients treated with imatinib

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Interaction of the common hOCT1 SNPs M420del and M408V is critical in predicting clinical outcome in chronic myeloid leukaemia patients treated with imatinib. In 16th Congress of the European Association of Haematology (pp. P89). London: EHA.

Conference Paper

The ABCC3 efflux transporter can predict clinical outcome in CML patients and is an important determinant of drug failure.

Giannoudis, A., Davies, A., Harris, R. J., Lucas, C. M., Francis, S., Pirmohamed, M., & Clark, R. E. (2011). The ABCC3 efflux transporter can predict clinical outcome in CML patients and is an important determinant of drug failure.. Haematologica, 96, S1-S678.

Journal article

2010

Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours

Muthana, M., Giannoudis, A., Scott, S. D., Mistry, R., Murdoch, C., Coffelt, S., . . . Lewis, C. E. (2010). Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. In DRUG DISCOVERY TODAY Vol. 15 (pp. 1097-1098). doi:10.1016/j.drudis.2010.09.398

DOI
10.1016/j.drudis.2010.09.398
Conference Paper

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.x

DOI
10.1111/j.1365-2141.2009.08066.x
Journal article

CORRELATION OF HOCT1 M420DEL SNP WITH THE CLINICAL OUTCOME OF CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH IMATINIB

Giannoudis, A., Wang, L., Xynarianos, G., Liloglou, T., Austin, G., Clark, J., . . . Clark, R. (2010). CORRELATION OF HOCT1 M420DEL SNP WITH THE CLINICAL OUTCOME OF CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH IMATINIB. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 341. Retrieved from https://www.webofscience.com/

Journal article

Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours

Muthana, M., Giannoudis, A., Scott, S. D., Mistry, R., Murdoch, C., Georgeopolous, L., . . . Lewis, C. E. (2010). Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. In HUMAN GENE THERAPY Vol. 21 (pp. 488). Retrieved from https://www.webofscience.com/

Conference Paper

HOCT1 M420 DELETED TRANSCRIPT LEVELS PREDICT POOR CLINICAL OUTCOME FOR IMATINIB TREATED CML PATIENTS

Wang, L., Giannoudis, A., Austin, G., Liloglou, T., Xinarianos, G., Clark, J., . . . Clark, R. (2010). HOCT1 M420 DELETED TRANSCRIPT LEVELS PREDICT POOR CLINICAL OUTCOME FOR IMATINIB TREATED CML PATIENTS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 61. Retrieved from https://www.webofscience.com/

Journal article

THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML

Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/

Journal article

The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.

Journal article

2009

Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134

DOI
10.3324/haematol.2009.009134
Journal article

A STUDY OF PLASMA LEVELS OF IMATINIB AND ITS BIOACTIVE METABOLITE CGP-74588 REVEALS NO CORRELATION WITH SUBSEQUENT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA

Davies, A., Hayes, A. K., Giannoudis, A., Lucas, C. M., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). A STUDY OF PLASMA LEVELS OF IMATINIB AND ITS BIOACTIVE METABOLITE CGP-74588 REVEALS NO CORRELATION WITH SUBSEQUENT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 94 (pp. 259). Retrieved from https://www.webofscience.com/

Conference Paper

FACS assessment of pCrKL/CrKL ratio at initial diagnosis is predictive of long term treatment outcome in chronic myeloid leukaemia (CML)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2009). FACS assessment of pCrKL/CrKL ratio at initial diagnosis is predictive of long term treatment outcome in chronic myeloid leukaemia (CML). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 145 (pp. 62). Retrieved from https://www.webofscience.com/

Conference Paper

Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166

DOI
10.1038/leu.2009.166
Journal article

2008

Human Papilloma Virus (HPV) and Host Cellular Interactions

Mammas, I. N., Sourvinos, G., Giannoudis, A., & Spandidos, D. A. (2008). Human Papilloma Virus (HPV) and Host Cellular Interactions. PATHOLOGY & ONCOLOGY RESEARCH, 14(4), 345-354. doi:10.1007/s12253-008-9056-6

DOI
10.1007/s12253-008-9056-6
Journal article

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. Blood, 112(11), 3205. doi:10.1182/blood.v112.11.3205.3205

DOI
10.1182/blood.v112.11.3205.3205
Journal article

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236

DOI
10.1182/blood-2007-10-116236
Journal article

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823

DOI
10.1080/10428190701858823
Journal article

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI
10.1038/sj.clpt.6100268
Journal article

Dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression, in contrast to imatinib

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression, in contrast to imatinib. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 41). Retrieved from https://www.webofscience.com/

Conference Paper

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI
10.1038/sj.clpt.6100268
Journal article

Nilotinib concentration in Cell Lines and CML CD34+Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. In BLOOD Vol. 112 (pp. 1100). Retrieved from https://www.webofscience.com/

Conference Paper

THE HUMAN ORGANIC CATION TRANSPORTER I HAS MINIMAL IMPACT IN THE UPTAKE OF DASATINIB INTO CHRONIC MYELOID LEUKAEMIA PRIMARY CELLS AND CELL LINES

Giannoudis, A., Lucas, C. M., Davies, A., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). THE HUMAN ORGANIC CATION TRANSPORTER I HAS MINIMAL IMPACT IN THE UPTAKE OF DASATINIB INTO CHRONIC MYELOID LEUKAEMIA PRIMARY CELLS AND CELL LINES. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 312). Retrieved from https://www.webofscience.com/

Conference Paper

Unlike imatinib, nilotinib transport into chronic myeloid leukaemia cells is not dependent on hOCT1 expression

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2008). Unlike imatinib, nilotinib transport into chronic myeloid leukaemia cells is not dependent on hOCT1 expression. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 41-42). Retrieved from https://www.webofscience.com/

Conference Paper

2007

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 110(11), 2364. doi:10.1182/blood.v110.11.2364.2364

DOI
10.1182/blood.v110.11.2364.2364
Journal article

Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2007). Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression. In BLOOD Vol. 110 (pp. 1013A-1014A). doi:10.1182/blood.V110.11.3458.3458

DOI
10.1182/blood.V110.11.3458.3458
Conference Paper

Characterisation of nilotinib transport in chronic myeloid leukaemia cells

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of nilotinib transport in chronic myeloid leukaemia cells. In BLOOD Vol. 110 (pp. 698A). Retrieved from https://www.webofscience.com/

Conference Paper

2006

Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.

Wang, L., Giannoudis, A., Lane, S., Williamson, P. R., Pirmohamed, M., & Clark, R. E. (2006). Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.. In BLOOD Vol. 108 (pp. 608A-609A). doi:10.1182/blood.V108.11.2145.2145

DOI
10.1182/blood.V108.11.2145.2145
Conference Paper

Gene therapy for prostate cancer: Current strategies and new cell-based approaches

MacRae, E. J., Giannoudis, A., Ryan, R., Brown, N. J., Hamdy, F. C., Maitland, N., & Lewis, C. E. (2006). Gene therapy for prostate cancer: Current strategies and new cell-based approaches. PROSTATE, 66(5), 470-494. doi:10.1002/pros.20388

DOI
10.1002/pros.20388
Journal article

Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors

Muthana, M., Giannoudis, A., Scott, S. D., Burke, B., Mistry, R., Hamdy, F., . . . Lewis, C. E. (2006). Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, 66(8). Retrieved from https://www.webofscience.com/

Journal article

Imatinib and human organic cation transporter 1 (hOCT1): Characterisation of transport in a stably transfected myeloid cell line, and relationship of hOCT1 expression to cytogenetic response

Wang, L., Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2006). Imatinib and human organic cation transporter 1 (hOCT1): Characterisation of transport in a stably transfected myeloid cell line, and relationship of hOCT1 expression to cytogenetic response. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 118). Retrieved from https://www.webofscience.com/

Conference Paper

2004

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues

Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. BLOOD, 104(8), 2224-2234. doi:10.1182/blood-2004-03-1109

DOI
10.1182/blood-2004-03-1109
Journal article

2003

Hypoxia-induced gene expression in human macrophages - Implications for ischemic tissues and hypoxia-regulated gene therapy

Burke, B., Giannoudis, A., Corke, K. P., Gill, D., Wells, M., Ziegler-Heitbrock, L., & Lewis, C. E. (2003). Hypoxia-induced gene expression in human macrophages - Implications for ischemic tissues and hypoxia-regulated gene therapy. AMERICAN JOURNAL OF PATHOLOGY, 163(4), 1233-1243. doi:10.1016/S0002-9440(10)63483-9

DOI
10.1016/S0002-9440(10)63483-9
Journal article

2001

Human papillomavirus in pterygium

Gallagher, M. J., Giannoudis, A., Herrington, C. S., & Hiscott, P. (2001). Human papillomavirus in pterygium. BRITISH JOURNAL OF OPHTHALMOLOGY, 85(7), 782-784. doi:10.1136/bjo.85.7.782

DOI
10.1136/bjo.85.7.782
Journal article

Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix

Giannoudis, A., van Duin, M., Snijders, P. J. F., & Herrington, C. S. (2001). Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix. BRITISH JOURNAL OF CANCER, 84(8), 1058-1063. doi:10.1054/bjoc.2001.1695

DOI
10.1054/bjoc.2001.1695
Journal article

Human papillomavirus variants and squamous neoplasia of the cervix

Giannoudis, A., & Herrington, C. S. (2001). Human papillomavirus variants and squamous neoplasia of the cervix. JOURNAL OF PATHOLOGY, 193(3), 295-302. Retrieved from https://www.webofscience.com/

Journal article

2000

Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses

Giannoudis, A., & Herrington, C. S. (2000). Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. CANCER, 89(6), 1300-1307. doi:3.0.CO;2-U">10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U

DOI
10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U
Journal article

"High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa

Bouda, M., Gorgoulis, V. G., Kastrinakis, N. G., Giannoudis, A., Tsoli, E., Danassi-Afentaki, D., . . . Kittas, C. (2000). "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. MODERN PATHOLOGY, 13(6), 644-653. doi:10.1038/modpathol.3880113

DOI
10.1038/modpathol.3880113
Journal article

Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific

Giannoudis, A., Evans, M. F., Southern, S. A., & Herrington, C. S. (2000). Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific. BRITISH JOURNAL OF CANCER, 82(2), 424-428. doi:10.1054/bjoc.1999.0937

DOI
10.1054/bjoc.1999.0937
Journal article

High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection

Sheard, J. D. H., Vijayanand, R., Herrington, C. S., Giannoudis, A., & Shaw, G. (2000). High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection. HISTOPATHOLOGY, 37(1), 87-88. Retrieved from https://www.webofscience.com/

Journal article

High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection.

Sheard, J. D., Vijayanand, R., Herrington, C. S., Giannoudis, A., & Shaw, G. (2000). High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection.. Histopathology, 37(1), 87-88. doi:10.1046/j.1365-2559.2000.00955-4.x

DOI
10.1046/j.1365-2559.2000.00955-4.x
Journal article

Human papilloma virus in pterygium.

Gallagher, M. J., Giannoudis, A., Hiscott, P., & Herrington, C. S. (2000). Human papilloma virus in pterygium.. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 41(4), S129. Retrieved from https://www.webofscience.com/

Journal article

1999

p53 codon 72 arg/pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix

Giannoudis, A., Graham, D. A., Southern, S. A., & Herrington, C. S. (1999). p53 codon 72 arg/pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. INTERNATIONAL JOURNAL OF CANCER, 83(1), 66-69. doi:3.0.CO;2-K">10.1002/(SICI)1097-0215(19990924)83:1<66::AID-IJC13>3.0.CO;2-K

DOI
10.1002/(SICI)1097-0215(19990924)83:1<66::AID-IJC13>3.0.CO;2-K
Journal article

Disruption of cell cycle regulators by human papillomaviruses in low grade squamous intraepithelial lesions of the cervix

Giannoudis, A., & Herrington, C. S. (1999). Disruption of cell cycle regulators by human papillomaviruses in low grade squamous intraepithelial lesions of the cervix. In JOURNAL OF MEDICAL GENETICS Vol. 36 (pp. S41). Retrieved from https://www.webofscience.com/

Conference Paper

Increased prevalence of an HPV-16 E2 mutation across the spectrum of cervical intraepithelial neoplasia.

Giannoudis, A., Graham, D. A., Southern, S. A., & Herrington, C. S. (1999). Increased prevalence of an HPV-16 E2 mutation across the spectrum of cervical intraepithelial neoplasia.. In BRITISH JOURNAL OF CANCER Vol. 80 (pp. 78). Retrieved from https://www.webofscience.com/

Conference Paper

1998

High risk human papillomaviruses can induce numerical chromosome abnormalities in low-grade squamous intraepithelial lesions

Giannoudis, A., Southern, S. A., & Herrington, C. S. (1998). High risk human papillomaviruses can induce numerical chromosome abnormalities in low-grade squamous intraepithelial lesions. In BRITISH JOURNAL OF CANCER Vol. 78 (pp. 71). Retrieved from https://www.webofscience.com/

Conference Paper

1995

DETECTION OF EPSTEIN-BARR-VIRUS AND HUMAN PAPILLOMAVIRUS IN NASOPHARYNGEAL CARCINOMA BY THE POLYMERASE CHAIN-REACTION TECHNIQUE

GIANNOUDIS, A., ERGAZAKI, M., SEGAS, J., GIOTAKIS, J., ADAMOPOULOS, G., GORGOULIS, V., & SPANDIDOS, D. A. (1995). DETECTION OF EPSTEIN-BARR-VIRUS AND HUMAN PAPILLOMAVIRUS IN NASOPHARYNGEAL CARCINOMA BY THE POLYMERASE CHAIN-REACTION TECHNIQUE. CANCER LETTERS, 89(2), 177-181. doi:10.1016/0304-3835(94)03667-8

DOI
10.1016/0304-3835(94)03667-8
Journal article

1994

DETECTION OF HSV, CMV AND EBV BY THE POLYMERASE CHAIN-REACTION TECHNIQUE IN PATIENTS WITH INFLAMMATORY EYE-DISEASES

ERGAZAKI, M., XINARIANOS, G., GIANNOUDIS, A., MARKOMICHELAKIS, N., TSAMPARLAKIS, J., & SPANDIDOS, D. A. (1994). DETECTION OF HSV, CMV AND EBV BY THE POLYMERASE CHAIN-REACTION TECHNIQUE IN PATIENTS WITH INFLAMMATORY EYE-DISEASES. ONCOLOGY REPORTS, 1(6), 1207-1210. Retrieved from https://www.webofscience.com/

Journal article

DETECTION OF HUMAN CYTOMEGALOVIRUS AND EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN PATIENTS WITH BETA-THALASSEMIA

ERGAZAKI, M., XINARIANOS, G., GIANNOUDIS, A., KOFFA, M., LILOGLOU, T., KATTAMIS, C., & SPANDIDOS, D. A. (1994). DETECTION OF HUMAN CYTOMEGALOVIRUS AND EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN PATIENTS WITH BETA-THALASSEMIA. ONCOLOGY REPORTS, 1(4), 813-816. Retrieved from https://www.webofscience.com/

Journal article

DETECTION OF THE EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED PATIENTS

LILOGLOU, T., GIANNOUDIS, A., ERGAZAKI, M., KOFFA, M., & SPANDIDOS, D. A. (1994). DETECTION OF THE EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED PATIENTS. ONCOLOGY REPORTS, 1(4), 809-811. Retrieved from https://www.webofscience.com/

Journal article

THE PRESENCE OF HERPESVIRUSES IN PTERYGIUM

SPANDIDOS, D. A., XINARIANOS, G., ERGAZAKI, M., GIANNOUDIS, A., & TSAMPARLAKIS, J. (1994). THE PRESENCE OF HERPESVIRUSES IN PTERYGIUM. INTERNATIONAL JOURNAL OF ONCOLOGY, 5(4), 749-752. Retrieved from https://www.webofscience.com/

Journal article